



## NOTIFICATION OF DISTRIBUTION OF SUBSTANTIAL HOLDER SHARES

In accordance with the Deed of Undertaking entered into between REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) and ASX Limited, the Company provides ASX with the following information in relation to substantial holdings in the Company.

Saints Capital Everest, L.P. has notified REVA that they have distributed 29,011,707 CDIs previously held to their limited partners as of January 10, 2018. See attached Schedule 13G/A filed by Saints Capital Everest, L.P. with the United States Securities and Exchange Commission.

### 1 CEASING TO BE A SUBSTANTIAL SHAREHOLDER

<b>Name:</b>	Saints Capital Everest, L.P.
<b>Date holder ceased to be a substantial holder:</b>	January 10, 2018

Brandi Roberts  
Company Secretary  
January 11, 2018

### About REVA

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead product, the Phantom® bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the United States and Europe.

### Forward-Looking Statements

*This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-*

*looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on February 28, 2017, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

**United States****Investor & Media Enquiries:**

REVA Medical, Inc.  
Brandi Roberts  
Chief Financial Officer  
+1 858-966-3003  
Cheryl Liberatore  
Director, Communications  
+1 858-966-3045  
ir@revamedical.com

**Australia****Investor Enquiries:**

Inteq Limited  
Kim Jacobs  
+61 438 217 279  
Andrew Cohen  
+61 408 333 452

**Australia****Media Enquiries:**

Buchan Consulting  
Rebecca Wilson  
+61 3 9866 4722

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**SCHEDULE 13G/A**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 1)\***

---

**REVA Medical, Inc.**  
(Name of Issuer)

**COMMON STOCK, PAR VALUE \$0.0001 PER SHARE**  
(Title of Class of Securities)

**76133E109**  
(CUSIP Number)

**December 31, 2016**  
(Date of Event Which Requires Filing of this Statement)

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the Notes).

---

---

1.	NAMES OF REPORTING PERSONS	
	Saints Capital Everest, L.P.	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
		2,901,171
	6.	SHARED VOTING POWER
		0
	7.	SOLE DISPOSITIVE POWER
		2,901,171
	8.	SHARED DISPOSITIVE POWER
		0
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	2,901,171 (1)	
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
	N/A	
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	
	6.8% (2)	
12.	TYPE OF REPORTING PERSON	
	PN	

- (1) Held in the form of CHESS Depository Interests (“CDIs”) on the Australian Securities Exchange; each share of Common Stock is equivalent to ten CDIs.
- (2) The percentage is calculated based on 42,851,477 shares of Common Stock outstanding on February 15, 2017 as reported in the Issuer’s Form 10-K filed on February 28, 2017.

1.	NAMES OF REPORTING PERSONS	
	Saints Capital Everest, LLC	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
		2,901,171
	6.	SHARED VOTING POWER
		0
	7.	SOLE DISPOSITIVE POWER
		2,901,171
	8.	SHARED DISPOSITIVE POWER
		0
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	2,901,171 (1)	
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
	N/A	
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	
	6.8% (2)	
12.	TYPE OF REPORTING PERSON	
	OO	

CUSIP No. 76133E109

13G/A

Page 4 of 8

**Item 1(a). Name of Issuer:**

REVA Medical, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**

REVA Medical, Inc.  
5751 Copley Drive  
San Diego, CA 92111

**Item 2(a). Name of Persons Filing:**

This statement is filed on behalf of the following persons with respect to shares of Common Stock beneficially owned by such persons:

- (i) Saints Capital Everest, L.P., a Delaware limited partnership (the "Fund"); and
- (ii) Saints Capital Everest, LLC, a Delaware limited liability company (the "General Partner")

The foregoing persons are hereinafter referred to collectively as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

**Item 2(b). Address of Principal Business Office or, if None, Residence:**

The address of the principal business office of the Reporting Persons is:

2020 Union Street  
San Francisco, CA 94123

**Item 2(c). Citizenship:**

The Fund is a limited partnership organized under the laws of the State of Delaware.

The General Partner is a limited liability company organized under the laws of the State of Delaware.

**Item 2(d). Title of Class of Securities:**

Common Stock, par value \$0.0001 per share (the "Common Stock").

**Item 2(e). CUSIP Number:**

76133E109

**Item 3.**

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under Section 15 of the Act;
- (b)  Bank as defined in Section 3(a)(6) of the Act;
- (c)  Insurance company as defined in Section 3(a)(19) of the Act;
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940;
- (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with §240.13d-1 (b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act;
- (j)  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
- (k)  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13(d)-1(b)(1)(ii)(J), please specify the type of institution: \_\_\_\_\_.

#### Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) and (b) Amount beneficially owned and Percent of Class:

<u>Reporting Person</u>	<u>Shares</u>	<u>Percent</u>
Saints Capital Everest, LP (1)	2,901,171(2)	6.8%
Saints Capital Everest, LLC(3)	2,901,171(2)	6.8%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote:

<u>Reporting Person</u>	<u>Shares</u>
Saints Capital Everest, LP	2,901,171(2)
Saints Capital Everest, LLC	2,901,171(2)

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of:

<u>Reporting Person</u>	<u>Shares</u>
Saints Capital Everest, LP	2,901,171(2)
Saints Capital Everest, LLC	2,901,171(2)

(iv) Shared power to dispose or to direct the disposition of: 0

- (1) The Fund directly owns 2,901,171 shares of Common Stock (the "Shares"), which represents approximately 6.8% of the outstanding shares of Common Stock.
- (2) Held in the form of CHESSE Depository Interests ("CDIs") on the Australian Securities Exchange; each share of Common Stock is equivalent to ten CDIs.
- (3) As the general partner of the Fund, the General Partner may be deemed to beneficially own the Shares.

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Not applicable.

**Item 8. Identification and Classification of Members of the Group.**

Not applicable.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certification.**

Not applicable.



CUSIP No. 76133E109

13G/A

Page 7 of 8

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 9, 2017

SAINTS CAPITAL EVEREST, L.P.

By: Saints Capital Everest, LLC,  
Its General PartnerBy: /s/ Scott Halsted  
\_\_\_\_\_  
Scott Halsted, Managing Member

SAINTS CAPITAL EVEREST, LLC

By: /s/ Scott Halsted  
\_\_\_\_\_  
Scott Halsted, Managing Member

## Schedule of Exhibits

**SCHEDULE 13G**

<u>Exhibit Number</u>	<u>Exhibit Description</u>
1	Joint Filing Agreement

EX-99.1 2 d397294dex991.htm EX-99.1

**EXHIBIT 1****JOINT FILING AGREEMENT**

In accordance with Rule 16a-3(j) and Rule 13d-1(k)(1) and under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of Forms 3, 4, 5 and Schedules 13D and 13G (including any and all amendments thereto) with respect to the Common Stock, par value \$0.0001 per share, of REVA Medical, Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Forms 3, 4, 5 and Schedules 13D and 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided that no party is responsible for the completeness or accuracy of the information concerning any other filing party, unless such party knows or has reason to believe that such information is inaccurate.

This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.

In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of May 9, 2017.

SAINTS CAPITAL EVEREST, L.P.

By: Saints Capital Everest, LLC,  
Its General PartnerBy: /s/ Scott Halsted  
Scott Halsted, Managing Member

SAINTS CAPITAL EVEREST, LLC

By: /s/ Scott Halsted  
Scott Halsted, Managing Member